

Short Name	Comments	Type	Investigator	Contact
Disease site specific				
Acute Kidney Disease				
Gambro HF-20	<p>Clinical Evaluation of the Prismaflex HF20 Set and Prismaflex® System 7.10 for Acute Continuous Renal Replacement Therapy (CRRT) in Children</p> <p><i>This research study involves children who are admitted to the PICU and require Continuous Renal Replacement Therapy (CRRT) for treatment of an acute kidney injury. The purpose of the research is to evaluate the performance of the Gambro Prismaflex HF20 Set (a dialysis filter designed for small children) and the Prismaflex System 7.10 (the continuous dialysis machine) in delivering CRRT, in patients weighing between 8 kg (17.6 pounds) and 20 kg (44.09 pounds).</i></p> <p>For More Information</p>	Treatment	Dr. Richard Hackbarth	<p>Emily Gleason Emily.Gleason@helendevoschildrens.org 616.486.6332</p>
Chronic Kidney Disease				
CKiD	<p>Chronic Kidney Disease in Children Prospective Cohort Study</p> <p><i>Chronic Kidney Disease in Children Prospective Cohort Study (CKiD), two cohorts of patients (20;10) opening an amendment, committing to enrolling three cohorts of 10 more over next three years. We are one of 52 sites, E coast region led by CHOP. Third cohort open. Children need to be under five years of age.</i></p> <p>For More Information</p>	Registry	Dr. Jason Thomas	<p>Dan Bartolovic Danijel.Bartolovic@spectrumhealth.org Sarah Vos Sarah.Vos@helendevoschildrens.org</p>
NAPRTCS Registry	<p>NAPRTCS Registry</p> <p><i>The purpose of the registry is to enter scientific data on the care and treatment of pediatric kidney disease and transplantation into a national registry. Collecting this data into one nationwide registry is expected to improve medical care of children including those who have received renal transplants.</i></p>	Registry	Dr. Julia Steinke	<p>Julia Steinke, MD julia.steinke@spectrumhealth.org 616.267.2400</p>

Other

Cure GN	Cure Glomerulonephropathy Network	Registry	Dr. Jens Goebel	Sarah Vos sarah.vos@helendevoschildrens.org 616.486.2064
----------------	--	----------	-----------------	---

The purpose of the CureGN is to create a source of information so that researchers can easily and effectively study rare glomerular disease such as MCD, FSGS, MN and IgAN, the underlying causes, identify markers of disease, and identify and evaluate new therapies.

MWPNC GIGA	GIGA-kids Genomics of IgA related diseases in kids	Treatment	Dr. Alejandro Quiroga Chand	Sarah Vos sarah.vos@helendevoschildrens.org 616.486.2064
-------------------	---	-----------	-----------------------------	---

The purpose of this study will be to determine how some genes affect the development of IgAN and HSP by looking at biomarkers found in the blood. Normal, healthy children will also be enrolled in this study as matched controls and are required to perform adequate validations of biomarkers. IgA Nephropathy (IgAN) and Henoch-Schönlein Purpura (HSP) are related diseases, both thought to be due by deposits of the IgA antibody in the kidney. IgA nephropathy (IgAN) represents the leading cause of kidney failure among young adults, and the most frequent form of primary glomerulonephritis worldwide.

Kaneka Liposorber LA-15 PAS	Treatment of Drug-resistant Pediatric Primary Focal Segmental Glomerulosclerosis Using the Liposorber® LA-15 System: Post Approval Study	Observational	Dr. Alejandro Quiroga Chand	Emily Gleason Emily.Gleason@helendevoschildrens.org 616.486.6332
------------------------------------	---	---------------	-----------------------------	---

This is an observational research study for patients who have agreed to receive treatment with the Liposorber System. An observational study is a type of research in which individuals are observed over a period of time to measure outcomes, and no changes are made to the treatment participants receive. For this study we will collect information (or “data”) about your health and your treatment with the Liposorber system, and we will collect blood and urine samples at some visits for research lab tests. The information collected from study participants will be used to further evaluate the safety and probable benefit of this treatment.